290 related articles for article (PubMed ID: 37438819)
1. Indole-based FLT3 inhibitors and related scaffolds as potential therapeutic agents for acute myeloid leukemia.
Ezelarab HAA; Ali TFS; Abbas SH; Hassan HA; Beshr EAM
BMC Chem; 2023 Jul; 17(1):73. PubMed ID: 37438819
[TBL] [Abstract][Full Text] [Related]
2. Emerging treatment paradigms with FLT3 inhibitors in acute myeloid leukemia.
Short NJ; Kantarjian H; Ravandi F; Daver N
Ther Adv Hematol; 2019; 10():2040620719827310. PubMed ID: 30800259
[TBL] [Abstract][Full Text] [Related]
3. Gilteritinib: a novel FLT3 inhibitor for acute myeloid leukemia.
Zhao J; Song Y; Liu D
Biomark Res; 2019; 7():19. PubMed ID: 31528345
[TBL] [Abstract][Full Text] [Related]
4. The role of small molecule Flt3 receptor protein-tyrosine kinase inhibitors in the treatment of Flt3-positive acute myelogenous leukemias.
Roskoski R
Pharmacol Res; 2020 May; 155():104725. PubMed ID: 32109580
[TBL] [Abstract][Full Text] [Related]
5. Emerging FLT3 inhibitors for the treatment of acute myeloid leukemia.
Solana-Altabella A; Ballesta-López O; Megías-Vericat JE; Martínez-Cuadrón D; Montesinos P
Expert Opin Emerg Drugs; 2022 Mar; 27(1):1-18. PubMed ID: 35076348
[TBL] [Abstract][Full Text] [Related]
6. A review of FLT3 inhibitors in acute myeloid leukemia.
Zhao JC; Agarwal S; Ahmad H; Amin K; Bewersdorf JP; Zeidan AM
Blood Rev; 2022 Mar; 52():100905. PubMed ID: 34774343
[TBL] [Abstract][Full Text] [Related]
7. Clinical considerations for the use of FLT3 inhibitors in acute myeloid leukemia.
Weis TM; Marini BL; Bixby DL; Perissinotti AJ
Crit Rev Oncol Hematol; 2019 Sep; 141():125-138. PubMed ID: 31279288
[TBL] [Abstract][Full Text] [Related]
8. Midostaurin In Acute Myeloid Leukemia: An Evidence-Based Review And Patient Selection.
Abbas HA; Alfayez M; Kadia T; Ravandi-Kashani F; Daver N
Cancer Manag Res; 2019; 11():8817-8828. PubMed ID: 31632141
[No Abstract] [Full Text] [Related]
9. Incorporating FLT3 inhibitors in the frontline treatment of FLT3 mutant acute myeloid leukemia.
Wang ES
Best Pract Res Clin Haematol; 2019 Jun; 32(2):154-162. PubMed ID: 31203997
[TBL] [Abstract][Full Text] [Related]
10. Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia.
Mori M; Kaneko N; Ueno Y; Yamada M; Tanaka R; Saito R; Shimada I; Mori K; Kuromitsu S
Invest New Drugs; 2017 Oct; 35(5):556-565. PubMed ID: 28516360
[TBL] [Abstract][Full Text] [Related]
11. [FLT3 inhibitors in the treatment of FLT3-mutated acute myeloid leukemia].
Kawashima N
Rinsho Ketsueki; 2021; 62(8):954-966. PubMed ID: 34497236
[TBL] [Abstract][Full Text] [Related]
12. FLT3 Inhibition in Acute Myeloid Leukaemia - Current Knowledge and Future Prospects.
Hogan FL; Williams V; Knapper S
Curr Cancer Drug Targets; 2020; 20(7):513-531. PubMed ID: 32418523
[TBL] [Abstract][Full Text] [Related]
13. FLT3 inhibitors for acute myeloid leukemia: successes, defeats, and emerging paradigms.
Acharya B; Saha D; Armstrong D; Lakkaniga NR; Frett B
RSC Med Chem; 2022 Jul; 13(7):798-816. PubMed ID: 35923716
[TBL] [Abstract][Full Text] [Related]
14. Effects of the multi-kinase inhibitor midostaurin in combination with chemotherapy in models of acute myeloid leukaemia.
Weisberg E; Meng C; Case AE; Tiv HL; Gokhale PC; Buhrlage SJ; Yang J; Liu X; Wang J; Gray N; Adamia S; Sattler M; Stone R; Griffin JD
J Cell Mol Med; 2020 Mar; 24(5):2968-2980. PubMed ID: 31967735
[TBL] [Abstract][Full Text] [Related]
15. Megakaryocytic Expansion in Gilteritinib-Treated Acute Myeloid Leukemia Patients Is Associated With AXL Inhibition.
Suknuntha K; Choi YJ; Jung HS; Majumder A; Shah S; Slukvin I; Ranheim EA
Front Oncol; 2020; 10():585151. PubMed ID: 33363015
[TBL] [Abstract][Full Text] [Related]
16. Safety of FLT3 inhibitors in patients with acute myeloid leukemia.
Cerchione C; Peleteiro Raíndo A; Mosquera Orgueira A; Mosquera Torre A; Bao Pérez L; Marconi G; Isidori A; Pérez Encinas MM; Martinelli G
Expert Rev Hematol; 2021 Sep; 14(9):851-865. PubMed ID: 34424108
[No Abstract] [Full Text] [Related]
17. Perspectives and challenges of small molecule inhibitor therapy for FLT3-mutated acute myeloid leukemia.
Lap CJ; Abrahim MS; Nassereddine S
Ann Hematol; 2023 Nov; ():. PubMed ID: 37975931
[TBL] [Abstract][Full Text] [Related]
18. FMS-Like Tyrosine Kinase 3 Inhibitors for the Treatment of Acute Myeloid Leukemia.
Novatcheva ED; Anouty Y; Saunders I; Mangan JK; Goodman AM
Clin Lymphoma Myeloma Leuk; 2022 Mar; 22(3):e161-e184. PubMed ID: 34649791
[TBL] [Abstract][Full Text] [Related]
19. FLT3 inhibitors in acute myeloid leukaemia: assessment of clinical effectiveness, adverse events and future research-a systematic review and meta-analysis.
Majothi S; Adams D; Loke J; Stevens SP; Wheatley K; Wilson JS
Syst Rev; 2020 Dec; 9(1):285. PubMed ID: 33287892
[TBL] [Abstract][Full Text] [Related]
20. FLT3 inhibitors in the treatment of acute myeloid leukemia: current status and future perspectives.
Mosquera Orgueira A; Bao Pérez L; Mosquera Torre A; Peleteiro Raíndo A; Cid López M; Díaz Arias JÁ; Ferreiro Ferro R; Antelo Rodríguez B; González Pérez MS; Albors Ferreiro M; Alonso Vence N; Pérez Encinas MM; Bello López JL; Martinelli G; Cerchione C
Minerva Med; 2020 Oct; 111(5):427-442. PubMed ID: 32955823
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
